Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Newly identified genes may help predict outcome in childhood leukemia

08.12.2003


The measurement of new genes at diagnosis in children with acute lymphoblastic leukemia (ALL), discovered through new technologies from the human genome project, may be highly predictive of therapeutic outcomes, according to a study presented today during the 45th Annual Meeting of the American Society of Hematology (ASH). OPAL 1 (Outcome Predictor in Acute Leukemia 1), a novel, fully cloned human gene, and additional newly identified genes, have a strong predictive power to identify patients who may achieve remission or fail current therapeutic regimens for pediatric ALL, allowing physicians to tailor therapies more effectively to individual children with leukemia.



Study results showed that 87 percent of the patients with ALL and high OPAL 1 achieved long-term remission, compared to an overall outcome of 32 percent of all patients studied. OPAL1 was also highly predictive of a favorable outcome in T-cell ALL, and a similar trend was observed in infant ALL. Low OPAL1 was associated with induction failure, while high OPAL1 was associated with long-term event free survival, particularly in males. Eighty-six percent of ALL cases with t(12;21), which has prognostic value in ALL, and high OPAL1 achieved long term remission compared to only 35 percent of t(12;21) cases with low OPAL1, suggesting that OPAL1 may be useful in prospectively identifying children who may benefit from further intensification.

"Our study confirms that gene expression profiling can yield novel genes that may be used to improve risk classification and outcome prediction in acute leukemia in children," said Cheryl L. Willman, M.D., of the University of New Mexico Health Sciences Center, Albuquerque, N.M., senior author of the study. "Improving risk classification schemes in order to precisely tailor treatment regimens to individual patients has long been a major challenge for pediatric ALL, and is a goal of the National Children’s Oncology Group and the National Cancer Institute, which have supported our work. We believe that our research brings us closer to achieving this goal."


Current treatments, usually combination chemotherapy and post-induction therapeutic intensification (increasingly stronger treatment administered after initial therapy), currently help 75 percent of children with ALL achieve long-term remission. Yet, 25 percent of patients relapse with resistant disease. Additionally, 25 percent of patients who receive dose intensification treatment are often over-treated and may be cured using less intensive regimens with fewer acute and long-term side effects.

To identify strongly predictive genes, researchers performed gene expression profiling in two large, statistically designed, retrospective groups of pediatric ALL patients registered to trials previously conducted by the Pediatric Oncology Group (now merged with other national groups into the Children’s Oncology Group) – a group of 127 infant leukemia patients and a case control study of 254 children with B-precursor and T-cell ALL. Researchers used unsupervised learning tools and supervised machine learning algorithms to identify novel genes that were predictive of outcomes. Three strong genes were identified with both testing methods – G0, an expressed sequence tag of previously unknown function; G1:GNB2L1, a G-protein (a second messenger receptor of intracellular response) and activator of protein kinase C, which plays a pivotal role in cell signaling systems; and G2, an interleukin (IL)-10 receptor alpha, which regulates immune and inflammatory response. ALL cases expressing higher levels of these genes were associated with better outcomes. As the group fully cloned and characterized the G0 expressed sequence tag, it was given the new name of OPAL1.

"Studies to profile gene expressions in cancers like leukemia are very timely because physicians still need to better predict therapeutic responses," said Ronald Hoffman, M.D., President of the American Society of Hematology. "While we can already use a combination of chemotherapy and post-therapeutic treatments to help most children with ALL achieve remission, it is still difficult to know which patients will experience a relapse in the disease when they become resistant to the therapy. Hopefully the identification of new genes will help hematologists more accurately treat patients."

Leukemia is a cancer of the white blood cells that starts in the bone marrow and spreads to the blood, lymph nodes, and other organs. Both children and adults can develop leukemia, which is a complex disease with many different types and sub-types. The kind of treatment given and the outlook for childhood leukemia vary greatly according to the exact type and other individual factors. In acute leukemia the cells grow rapidly and are not able to mature properly. According to the National Cancer Institute, the vast majority of children diagnosed with leukemia have an acute form of the disease. Leukemias account for more than 30 percent of childhood cancers in children younger than 15 years old; three-fourths of those cases are ALL. The disease is not known as an inherited type, but there is evidence that it tends to cluster in families with high incidences of cancer.


###
The American Society of Hematology is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Aimee Frank | EurekAlert!
Further information:
http://www.hematology.org/

More articles from Life Sciences:

nachricht New photocatalyst speeds up the conversion of carbon dioxide into chemical resources
29.05.2017 | DGIST (Daegu Gyeongbuk Institute of Science and Technology)

nachricht Copper hydroxide nanoparticles provide protection against toxic oxygen radicals in cigarette smoke
29.05.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>